Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

Stopped It was unlikely that the primary endpoint would be reached based on the fifth interim analysis results.

Conditions

• Recurrent Head and Neck Cancer
• Metastatic Head and Neck Cancer

Interventions

• DRUG: docetaxel
• OTHER: placebo
• DRUG: gefitinib

Sponsor

National Cancer Institute (NCI)